Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-TBI Conditioning for NGS-MRD Negative B-ALL
NCT03509961Phase 2Recruiting
- Sponsor
- Pediatric Transplant and Cellular Therapy Consortium
- Start
- Aug 2018
- Primary completion
- Jul 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of busulfan, fludarabine and thiotepa in B cell acute lymphoblastic leukemia (B-ALL) (2 arms), sponsored by Pediatric Transplant and Cellular Therapy Consortium. Primary endpoint: Event-free Survival at 2 years. Started Aug 2018; status: recruiting.
02
Drugs
busulfanfludarabinethiotepa
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03509961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03509961.